{
  "id": 20977605,
  "title": "Glaukos CFO Alex Thurman sells $3.55M in stock, exercises options",
  "url": "https://urgent.news/2026/11/21/glaukos-cfo-alex-thurman-sells-3-55m-in-stock-exercises-options",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-21T01:01:03.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/glaukos-cfo-alex-thurman-sells-355m-in-stock-exercises-options-93CH-5042983"
  },
  "original_language": "en",
  "account": "Glaukos Corp CFO Alex Thurman sold 14,800 shares of the company's stock for $3,553,763 on November 18, 2026. This sale happened as the stock price neared its 52-week high of $255.19, following an impressive 138% gain over the past year. However, InvestingPro analysis questioned whether the stock was undervalued at the time. Thurman's sales were carried out under a Rule 10b5-1 trading plan he implemented on August 18, 2026. The same plan also allowed for the exercise of certain stock options set to expire on March 15, 2027. On the same day, Thurman exercised options by purchasing 15,000 shares at $45.71 per share, totaling $685,650. This action was also part of his pre-set trading plan. After these transactions, Thurman’s direct ownership in Glaukos Corp stood at 43,906 shares, comprising 5,230 restricted stock units that had not yet vested. Analysts are optimistic about Glaukos' future, with 11 of them revising their earnings estimates upwards. Glaukos reported strong financials in the third quarter of 2026, with revenue increasing by 58% to $211 million, surpassing analyst expectations. The company's Epioxa segment played a significant role in this growth, showing improved profitability. Glaukos management raised its 2026 revenue guidance by 13% and projected a $1 billion revenue for 2027, exceeding previous estimates. Several analysts responded positively to these results, raising their stock price targets for Glaukos. BTIG increased its target to $252, H.C. Wainwright set it at $248, Piper Sandler to $240, Needham to $251, and Mizuho to $225. These updates indicate a favorable outlook for Glaukos based on its impressive financial performance.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}